Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NANCY A DAWSON

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1073571519
CMS profile
274972
Location
WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$180,947.06

109 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $37,100.00 10
Myovant Sciences Inc. $29,367.07 19
Seagen Inc. $27,671.91 18
AstraZeneca Pharmaceuticals LP $27,470.12 22
Janssen Biotech, Inc. $22,845.84 18
Eisai Inc. $11,021.71 6
Astellas Pharma US Inc $10,805.54 7
Exelixis Inc. $9,382.20 6
Merck Sharp & Dohme Corporation $2,750.00 1
Bayer HealthCare Pharmaceuticals Inc. $1,522.67 1
Janssen Scientific Affairs, LLC $1,010.00 1

Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NANCY A DAWSON

NPI 1073571519 · CMS profile ID 274972

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073571519?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NANCY A DAWSON, NPI 1073571519, CMS profile ID 274972. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073571519?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). NANCY A DAWSON, NPI 1073571519, CMS profile ID 274972. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073571519?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
NANCY A DAWSON, NPI 1073571519, CMS profile ID 274972, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1073571519?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

109 matching records · $180,947.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 109 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 109.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $471.4109/20/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788997493 CMS
Myovant Sciences Inc. $1,550.0009/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834950865 CMS
Exelixis Inc. $1,980.0009/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838871543 CMS
AstraZeneca Pharmaceuticals LP $1,050.0009/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829710853 CMS
Janssen Biotech, Inc. $111.1609/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788997487 CMS
Janssen Biotech, Inc. $71.5609/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788997479 CMS
Janssen Biotech, Inc. $366.1409/09/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788997481 CMS
Janssen Scientific Affairs, LLC $1,010.0009/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788997507 CMS
Astellas Pharma US Inc $730.0008/31/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821296789 CMS
Myovant Sciences Inc. $1,550.0008/31/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834950863 CMS
AstraZeneca Pharmaceuticals LP $1,370.0008/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830077677 CMS
AstraZeneca Pharmaceuticals LP $5,500.0008/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829926753 CMS
AstraZeneca Pharmaceuticals LP $1,712.5007/27/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829495437 CMS
Seagen Inc. $121.4007/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832184375 CMS
Seagen Inc. $4,380.0007/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832184387 CMS
Seagen Inc. $1,145.9507/21/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832184391 CMS
AstraZeneca Pharmaceuticals LP $124.9907/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829527437 CMS
AstraZeneca Pharmaceuticals LP $950.3507/14/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829594065 CMS
Seagen Inc. $124.8007/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832184371 CMS
Seagen Inc. $4,380.0007/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832184379 CMS
Seagen Inc. $1,062.2307/08/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832184383 CMS
Janssen Biotech, Inc. $1,000.0007/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788997475 CMS
PFIZER INC. $3,325.0006/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832894067 CMS
Janssen Biotech, Inc. $1,000.0006/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788997473 CMS
Seagen Inc. $83.1406/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832184355 CMS
Seagen Inc. $4,380.0006/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832184359 CMS
Seagen Inc. $1,084.4306/17/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832184363 CMS
PFIZER INC. $3,325.0006/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832933811 CMS
AstraZeneca Pharmaceuticals LP $2,750.0006/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829631249 CMS
Janssen Biotech, Inc. $1,000.0006/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788997471 CMS
AstraZeneca Pharmaceuticals LP $109.5606/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829777427 CMS
AstraZeneca Pharmaceuticals LP $76.8106/08/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830101563 CMS
PFIZER INC. $3,325.0006/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832941556 CMS
PFIZER INC. $3,325.0006/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832959881 CMS
PFIZER INC. $3,325.0006/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832937283 CMS
PFIZER INC. $7,500.0006/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832939185 CMS
PFIZER INC. $3,325.0005/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832909937 CMS
Merck Sharp & Dohme Corporation $2,750.0005/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848464793 CMS
Myovant Sciences Inc. $1,550.0005/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834950861 CMS
Janssen Biotech, Inc. $1,000.0005/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788997477 CMS
AstraZeneca Pharmaceuticals LP $2,750.0005/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829416491 CMS
AstraZeneca Pharmaceuticals LP $35.9304/27/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829740339 CMS
AstraZeneca Pharmaceuticals LP $125.0004/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830082897 CMS
Myovant Sciences Inc. $940.8004/09/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834950857 CMS
Myovant Sciences Inc. $6,590.0004/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834950859 CMS
Myovant Sciences Inc. $1,550.0004/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834950855 CMS
Myovant Sciences Inc. $1,550.0004/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834950849 CMS
Myovant Sciences Inc. $46.1404/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834950851 CMS
Myovant Sciences Inc. $82.8004/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834950853 CMS
Myovant Sciences Inc. $1,550.0003/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834950847 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $253,430.96 202
PY2020 $111,408.97 93
PY2021 $180,947.06 109
PY2022 $240,946.35 183
PY2023 $342,363.26 289
PY2024 $340,696.45 288
PY2025 $203,317.62 189

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,270.00 2
PY2025 Principal investigator $664,543.90 32
PY2024 Recipient $3,200.00 1
PY2024 Principal investigator $844,408.73 40
PY2023 Principal investigator $325,229.71 34
PY2022 Principal investigator $495,327.85 52
PY2021 Principal investigator $886,147.08 45
PY2020 Principal investigator $516,472.62 176
PY2019 Principal investigator $191,541.91 134

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $22,150.54 12/31/2025 Non-covered Recipient Entity
Georgetown University Medical Center
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle- No dispute reported 06/30/2026 1232927241
Principal investigator 1 Merck Sharp & Dohme LLC $11,215.36 12/31/2025 Non-covered Recipient Entity
Georgetown University Medical Center
A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy versus Perioperative Placebo Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE- No dispute reported 06/30/2026 1232927829
Principal investigator 1 Merck Sharp & Dohme LLC $30,142.60 12/01/2025 Non-covered Recipient Entity
Georgetown University Medical Center
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle- No dispute reported 06/30/2026 1232927239
Principal investigator 1 PFIZER INC. $524.80 11/26/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY ALONE IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER No dispute reported 06/30/2026 1228738275
Principal investigator 1 PFIZER INC. $17,225.00 11/25/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY ALONE IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER No dispute reported 06/30/2026 1228728035
Principal investigator 1 PFIZER INC. $46,207.89 11/18/2025 Covered Recipient Teaching Hospital
GEORGETOWN UNIVERSITY HOSPITAL
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228717487
Principal investigator 1 PFIZER INC. $46,207.89 11/18/2025 Covered Recipient Teaching Hospital
GEORGETOWN UNIVERSITY HOSPITAL
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228718251
Principal investigator 1 PFIZER INC. $3,117.40 11/14/2025 Non-covered Recipient Entity
Georgetown University
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228728107
Principal investigator 1 PFIZER INC. $262.40 10/14/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY ALONE IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER No dispute reported 06/30/2026 1228729859
Principal investigator 1 PFIZER INC. $11,863.00 10/09/2025 Non-covered Recipient Entity
Georgetown University
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228741552
Principal investigator 1 PFIZER INC. $46,207.89 08/26/2025 Covered Recipient Teaching Hospital
GEORGETOWN UNIVERSITY HOSPITAL
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228717489
Principal investigator 1 PFIZER INC. $46,207.89 08/26/2025 Covered Recipient Teaching Hospital
GEORGETOWN UNIVERSITY HOSPITAL
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228719481
Principal investigator 1 PFIZER INC. $3,794.70 08/14/2025 Non-covered Recipient Entity
Georgetown University
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228766729
Principal investigator 1 PFIZER INC. $262.40 06/16/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY ALONE IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER No dispute reported 06/30/2026 1228792134
Principal investigator 1 PFIZER INC. $677.30 06/07/2025 Non-covered Recipient Entity
Georgetown University
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228785427
Principal investigator 1 Merck Sharp & Dohme LLC $22,297.80 06/06/2025 Non-covered Recipient Entity
Georgetown University Medical Center
A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab MK-3475 Neoadjuvant Chemotherapy versus Perioperative Placebo Neoadjuvant Chemotherapy in Cisplatin-Eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE- No dispute reported 06/30/2026 1232927785
Principal investigator 1 PFIZER INC. $46,207.89 06/03/2025 Covered Recipient Teaching Hospital
GEORGETOWN UNIVERSITY HOSPITAL
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228755653
Principal investigator 1 PFIZER INC. $46,207.89 06/03/2025 Covered Recipient Teaching Hospital
GEORGETOWN UNIVERSITY HOSPITAL
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228756427
Recipient PFIZER INC. $940.00 05/31/2025 Covered Recipient Physician ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760005
Principal investigator 1 PFIZER INC. $3,117.40 04/29/2025 Non-covered Recipient Entity
Georgetown University
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228779639
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $32,075.00 04/16/2025 Non-covered Recipient Entity
Georgetown University
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) No dispute reported 06/30/2026 1235997153
Principal investigator 1 Janssen Research & Development, LLC $31,940.00 04/07/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Phase 3 Study of Erdafitinib Compared to Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations No dispute reported 06/30/2026 1175383630
Principal investigator 1 PFIZER INC. $262.40 04/07/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY ALONE IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER No dispute reported 06/30/2026 1228792085
Principal investigator 1 Janssen Research & Development, LLC $4,100.00 03/24/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
A Phase 3 Study of Erdafitinib Compared to Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations No dispute reported 06/30/2026 1175383593
Principal investigator 1 PFIZER INC. $677.30 03/14/2025 Non-covered Recipient Entity
Georgetown University
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228724240
Principal investigator 1 PFIZER INC. $3,117.40 02/22/2025 Non-covered Recipient Entity
Georgetown University
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228723478
Principal investigator 1 PFIZER INC. $46,207.89 02/11/2025 Covered Recipient Teaching Hospital
GEORGETOWN UNIVERSITY HOSPITAL
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228724056
Principal investigator 1 PFIZER INC. $46,207.89 02/11/2025 Covered Recipient Teaching Hospital
GEORGETOWN UNIVERSITY HOSPITAL
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228754637
Principal investigator 1 PFIZER INC. $524.80 02/10/2025 Non-covered Recipient Entity
GEORGETOWN UNIVERSITY
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY ALONE IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER No dispute reported 06/30/2026 1228801219
Principal investigator 1 PFIZER INC. $46,207.89 01/28/2025 Covered Recipient Teaching Hospital
GEORGETOWN UNIVERSITY HOSPITAL
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228757869
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770626
Principal investigator 1 PFIZER INC. $46,207.89 01/27/2025 Covered Recipient Teaching Hospital
GEORGETOWN UNIVERSITY HOSPITAL
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228758049
Principal investigator 1 PFIZER INC. $677.30 01/25/2025 Non-covered Recipient Entity
Georgetown University
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228720455
Principal investigator 1 PFIZER INC. $2,440.10 01/15/2025 Non-covered Recipient Entity
Georgetown University
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228798412